Emergent Biosolutions
EBS
253 hedge funds and large institutions have $1.86B invested in Emergent Biosolutions in 2021 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 87 increasing their positions, 94 reducing their positions, and 69 closing their positions.
2% more call options, than puts
Call options by funds: $6.64M | Put options by funds: $6.48M
7% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 94
3.42% less ownership
Funds ownership: 82.91% → 79.48% (-3.4%)
9% less funds holding
Funds holding: 277 → 253 (-24)
16% less capital invested
Capital invested by funds: $2.23B → $1.86B (-$367M)
32% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 69
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$102M |
| 2 |
D.E. Shaw & Co
New York
|
+$39.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.9M |
| 5 |
Millennium Management
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$120M |
| 2 |
Janus Henderson Group
London,
|
-$47.4M |
| 3 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$22.6M |
| 4 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$21.9M |
| 5 |
Goldman Sachs
New York
|
-$17.7M |
EBS Hedge Fund Activity: Q4 2021 in Review
253 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2021, worth a combined $1.86B — down 16% from $2.23B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of EBS and 47 opened new positions — a net loss of 22 holders — while 94 trimmed existing stakes and 87 added.
The largest buyer was BlackRock, adding an estimated $102M. The largest seller was Neuberger Berman Group, cutting an estimated $120M.
- 253 institutional investors held Emergent Biosolutions (EBS) as of Q4 2021, down from 277 in Q3 2021.
- Funds reported $1.86B of Emergent Biosolutions stock for Q4 2021, down 16% quarter-over-quarter.
- 47 funds opened new Emergent Biosolutions positions in Q4 2021 and 69 closed out, a net change of -22 holders.
- The largest Emergent Biosolutions buyer in Q4 2021 was BlackRock, an estimated $102M added.
- The largest Emergent Biosolutions seller in Q4 2021 was Neuberger Berman Group, an estimated $120M sold.
Based on aggregated 13F filings for Q4 2021.